• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

    Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

    JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

    JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

    AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

    AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

    ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

    ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

    TIER IV unveils end-to-end architecture for Level 4+ autonomy: To be demonstrated across 50 locations nationwide

    TIER IV unveils end-to-end architecture for Level 4+ autonomy: To be demonstrated across 50 locations nationwide

    Global Times: Xi’s vision of a people-centered city guides China’s urban development

    Global Times: Xi’s vision of a people-centered city guides China’s urban development

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Medisafe Scandal Deepens as HK Institutions Deny Outsourcing, Despite Contradictory Interview, Vendor Evidence and Whistleblower Claims

    Geneva Invention Awards Respond to Medisafe Scandal: ‘We Will Engage Our Own Panel to Determine Any Action’

    Deloitte: Over 40% of Family Offices Prioritise Tech Amid Digital Transformation

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    Hong Kong Student Criticised for Using Outsourced AI Project to Win STEM Awards

    Xiaomi SU7 Ultra Becomes Fastest Mass-Produced EV on Nürburgring Nordschleife

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

    Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

    JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

    JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

    AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

    AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

    ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

    ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

    TIER IV unveils end-to-end architecture for Level 4+ autonomy: To be demonstrated across 50 locations nationwide

    TIER IV unveils end-to-end architecture for Level 4+ autonomy: To be demonstrated across 50 locations nationwide

    Global Times: Xi’s vision of a people-centered city guides China’s urban development

    Global Times: Xi’s vision of a people-centered city guides China’s urban development

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Medisafe Scandal Deepens as HK Institutions Deny Outsourcing, Despite Contradictory Interview, Vendor Evidence and Whistleblower Claims

    Geneva Invention Awards Respond to Medisafe Scandal: ‘We Will Engage Our Own Panel to Determine Any Action’

    Deloitte: Over 40% of Family Offices Prioritise Tech Amid Digital Transformation

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    Hong Kong Student Criticised for Using Outsourced AI Project to Win STEM Awards

    Xiaomi SU7 Ultra Becomes Fastest Mass-Produced EV on Nürburgring Nordschleife

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

Yunji to Report Fourth Quarter and Full Year 2024 Financial Results on April 21, 2025

PR Newswire by PR Newswire
17 April 2025
in PR Newswire
0
Yunji to Report Fourth Quarter and Full Year 2024 Financial Results on April 21, 2025
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

HANGZHOU, China, April 17, 2025 /PRNewswire/ — Yunji Inc. (“Yunji” or the “Company”) (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that it plans to release its fourth quarter and full year 2024 financial results before the market opens on Monday, April 21, 2025. The earnings release will be available on the Company’s investor relations website at https://investor.yunjiglobal.com/.

The Company will hold a conference call on Monday, April 21, 2025 at 7:30 A.M. Eastern Time or 7:30 P.M. Beijing/Hong Kong Time to discuss its earnings. Listeners may access the call by dialing the following numbers:

International:

1-412-902-4272

United States Toll Free:

1-888-346-8982

Mainland China Toll Free:   

4001-201203

Hong Kong Toll Free:      

800-905945

Conference ID:  

Yunji Inc.

The replay will be accessible through April 28, 2025 by dialing the following numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Replay Access Code:

1068073

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://investor.yunjiglobal.com/.

About Yunji Inc.

Yunji Inc. is a leading social e-commerce platform in China that has pioneered a unique, membership-based model to leverage the power of social interactions. The Company’s e-commerce platform offers high-quality products at attractive prices across a wide variety of categories catering to the day-to-day needs of Chinese consumers. In addition, the Company uses advanced technologies including big data and artificial intelligence to optimize user experience and incentivize members to promote the platform as well as share products with their social contacts. Through deliberate product curation, centralized merchandise sourcing, and efficient supply chain management, Yunji has established itself as a trustworthy e-commerce platform with high-quality products and exclusive membership benefits, including discounted prices.

For more information, please visit https://investor.yunjiglobal.com/

Investor Relations Contact

Yunji Inc.
Investor Relations
Email: Yunji.IR@icrinc.com
Phone: +1 (646) 224-6957

ICR, LLC
Robin Yang
Email: Yunji.IR@icrinc.com
Phone: +1 (646) 224-6957

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

16 July 2025
JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

16 July 2025
  • Trending
  • Comments
  • Latest
CreateAI Advances Generative AI Technology with Two Papers Accepted at Prestigious ICCV 2025

CreateAI Advances Generative AI Technology with Two Papers Accepted at Prestigious ICCV 2025

2 July 2025
Taylor’s University Continues Strong Global Performance in QS World University Rankings 2026

Taylor’s University Continues Strong Global Performance in QS World University Rankings 2026

23 June 2025

PwC: Hong Kong Set to Reclaim Global IPO Crown in 2025 as Fundraising Surges

3 July 2025
FORTUNE UNVEILS 2025 SOUTHEAST ASIA 500

FORTUNE UNVEILS 2025 SOUTHEAST ASIA 500

17 June 2025
Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

16 July 2025
JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

16 July 2025
AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

16 July 2025
ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

16 July 2025

Recent News

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

16 July 2025
JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

JSRPM Leverages AI and Advanced Machining to Counter Tariff Pressures

16 July 2025
AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

AbbVie’s 10th ‘Week of Possibilities’ Unites Employees Across Asia for Community Impact

16 July 2025
ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

16 July 2025
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com